BIOAFFINITY TECHNOLOGIES INC
BIAFNASDAQTrading Snapshot
- Day Range
- $6.84 – $6.98
- 52-Week Range
- $4.56 – $109.35
- Volume
- $2.61B
- Avg Volume
- $1.90B
- Shares Outstanding
- 7.8M
- Next Earnings
- Nov 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-6.89
- Dividend Yield
- —
- Dilution (1yr)
- +316.7%
Why Investors Own BIAF
- ✓High-growth profile — revenue up -5.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BIOAFFINITY TECHNOLOGIES INC
BIAF
StockOtter · stockotter.spaceAbout BIOAFFINITY TECHNOLOGIES INC
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.
BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant
Shares of BioAffinity Technologies Inc. (NASDAQ:BIAF) are surging Thursday afternoon following the grant of a key Hong Kong patent for its CyPath Lung diagnostic. The rally is also boosting BioAffinity's Warrants (NASDAQ
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity announces new Hong Kong patent that protects the proprietary technology behind its noninvasive CyPath Lung diagnostic for lung cancer.
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies received notice that it has regained compliance with Nasdaq's applicable listing requirements.
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16.
BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?
Shares of bioAffinity Technologies Inc. (NASDAQ:BIAF) are surging Wednesday morning as traders digest recent commercial expansion announcements alongside tight low-float trading dynamics.